Lee Jones

Research Advocate

Lee was diagnosed with Stage IV colon cancer in March 2004 and after undergoing 18 rounds of chemotherapy and a liver resection in July 2006 has been cancer free. Lee has a BA in Psychology and an MBA in Finance and had a successful executive career in government, banking, consulting, and not-for-profit organizations. 

To help others survive and thrive after a cancer diagnosis, Lee became active with Fight Colorectal Cancer as a research advocate, and became a member of the Georgetown Oncology Institutional Review Board (IRB). He is a research advocate member of the SWOG Survivorship Committee and past patient member of the PCORI Clinical Trials Advisory Panel (CTAP); is on the Boards of the Cancer Action Coalition of Virginia (CACV), the Ruesch Center (Georgetown University), and the Cancer Policy and Advocacy Team (CPAT) of the National Coalition for Cancer Survivorship; has been a peer research proposal reviewer for ASCO, PCORI and the DOD; and is a member of ASCO, the National Colorectal Cancer Roundtable, and the Alliance for Regenerative Medicine (ARM). 

Lee has collaborated on several projects sponsored by The Friends of Cancer Research, including defining tolerability, reporting adverse events and tightening exclusion criteria, and has been a speaker at Ruesch Center, AAADV, CPAT, FDA and NCCN conferences. Lee has been appointed as a patient representative on the NCI’s Early Phase Emphasis Central IRB starting in January 2021, and is an advocate member of a multi-national team studying the relationship of the human microbiome and colorectal cancer.

As a cancer patient and survivor, Lee is committed to promoting the patient voice in cancer research, treatments, medical care, and the health care system in general.

His Role in Research Advocacy

  • Advocate member of international team studying the relationship between the human microbiome and CRC
  • Competitive selection to serve on the NCI Central IRB for early phase clinical trials
  • Serves as a research advocate with the SWOG Cancer Research Network and helping to launch a trial to improve quality of life for rectal cancer survivors